
-
Geron Corporation NASDAQ:GERN Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
Location: 919 East Hillsdale Boulevard, Suite 250, California, 94404, US | Website: www.geron.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
594.1M
Cash
406.6M
Avg Qtr Burn
-54.65M
Short % of Float
7.59%
Insider Ownership
0.09%
Institutional Own.
82.98%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome | Approved Quarterly sales | |
Imetelstat (GRN163L) Details Myelofibrosis | Phase 3 Interim Update | |
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 2 Data readout | |
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis | Phase 1b Data readout |